Chemical Structure : Rigosertib
CAS No.: 592542-59-1
Catalog No.: PC-42852Not For Human Use, Lab Use Only.
Rigosertib (ON 01910) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells.
Packing | Price | Stock | Quantity |
---|---|---|---|
10 mg | $98 | In stock | |
25 mg | $158 | In stock | |
50 mg | $258 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Rigosertib (ON 01910) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells.
Rigosertib (ON 01910) also exhibits inhibitory activity against PDGFR, Abl, and Flt-1, at higher concentrations, inhibits CDK1, Plk2, Src, and Fyn.
Rigosertib (ON 01910) demonstrates in vitro cytotoxicity against DU145 and K562 cells with IC50 of 100 and 15 nM.
Rigosertib (ON 01910) potently inhibits tumor growth in a variety of xenograft nude mouse models, does not exhibit hematotoxicity, liver damage, or neurotoxicity shows strong synergy with several chemotherapeutic agents.
M.Wt | 451.4901 | |
Formula | C21H25NO8S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]- |
1. Reddy MV, et al. J Med Chem. 2011 Sep 22;54(18):6254-76.
2. Gumireddy K, et al. Cancer Cell. 2005 Mar;7(3):275-86.
3. Oussenko IA, et al. Cancer Res. 2011 Jul 15;71(14):4968-76.
4. Chun AW, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright